Technical Analysis for ARNA - Arena Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade A 53.5 -0.94% -0.51
ARNA closed down 0.94 percent on Monday, May 20, 2019, on 1.28 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical ARNA trend table...

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Overbought Stochastic Strength 0.00%
Down 3 Days in a Row Weakness 0.00%
Stochastic Sell Signal Bearish -0.94%
Slingshot Bullish Bullish Swing Setup -0.94%
Calm After Storm Range Contraction -0.94%
NR7 Range Contraction -0.94%

Older signals for ARNA ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Arena Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company offers BELVIQ, a drug candidate approved by the United States food and drug administration for chronic weight management in adults. It is also involved in the development of APD811, an agonist of the prostacyclin receptor, which is in Phase I clinical trials for the treatment of pulmonary arterial hypertension; and temanogrel, an inverse agonist of the serotonin 2A receptor that is in Phase I clinical trials for the treatment of thrombotic diseases. In addition, the company's preclinical development products comprise APD334, an agonist of the S1P1 receptor intended for the treatment of autoimmune diseases; APD371, an agonist of the cannabinoid receptor 2 intended for the treatment of pain; and GPR119 agonists intended for the treatment of type 2 diabetes. Further, it manufactures drug products under a manufacturing services agreement. The company has a marketing and supply agreement with Ildong Pharmaceutical Co., Ltd. for the commercialization of BELVIQ in South Korea. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.
Chemistry Health Biopharmaceutical Food Pain Diabetes Medication Autoimmune Diseases Pharmacology Pulmonary Arterial Hypertension Metabolic Diseases Treatment Of Autoimmune Diseases Inflammatory Cannabinoids Chronic Weight Management Manufacturing Services Agreement United States Food And Drug Administration
Is ARNA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 58.0
52 Week Low 31.97
Average Volume 503,792
200-Day Moving Average 42.8851
50-Day Moving Average 47.3996
20-Day Moving Average 49.4665
10-Day Moving Average 52.444
Average True Range 2.3069
ADX 16.2
+DI 31.9017
-DI 22.7698
Chandelier Exit (Long, 3 ATRs ) 51.0793
Chandelier Exit (Short, 3 ATRs ) 49.4007
Upper Bollinger Band 56.7232
Lower Bollinger Band 42.2098
Percent B (%b) 0.78
BandWidth 29.339856
MACD Line 2.1138
MACD Signal Line 1.4985
MACD Histogram 0.6153
Fundamentals Value
Market Cap 2.1 Billion
Num Shares 39.2 Million
EPS -0.74
Price-to-Earnings (P/E) Ratio -72.30
Price-to-Sales 8.96
Price-to-Book 12.74
PEG Ratio 0.45
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 54.85
Resistance 3 (R3) 54.95 54.60 54.63
Resistance 2 (R2) 54.60 54.26 54.55 54.55
Resistance 1 (R1) 54.05 54.04 54.33 53.95 54.47
Pivot Point 53.70 53.70 53.84 53.65 53.70
Support 1 (S1) 53.15 53.36 53.43 53.05 52.53
Support 2 (S2) 52.80 53.14 52.75 52.45
Support 3 (S3) 52.25 52.80 52.38
Support 4 (S4) 52.15